<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000961</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG 131</org_study_id>
    <nct_id>NCT00000961</nct_id>
  </id_info>
  <brief_title>The Safety and Effectiveness of Hyperimmune Anti-HIV Intravenous Immunoglobulin (HVIG) Plus Zidovudine in HIV-Infected Infants</brief_title>
  <official_title>A Phase II Study to Evaluate the Safety, Tolerance and Efficacy of Hyperimmune Anti-HIV Intravenous Immunoglobulin (HIVIG) and of Zidovudine (ZDV) in Infants With Documented HIV Infections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Glaxo Wellcome</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      To determine the safety and tolerance of hyperimmune anti-HIV intravenous immunoglobulin&#xD;
      (HIVIG) and of zidovudine (AZT) in infants with established HIV infection; to get preliminary&#xD;
      evidence for the effectiveness of this type of treatment in preventing the advance of disease&#xD;
      in HIV infected infants. HIVIG may be an effective agent that either alone or in combination&#xD;
      with AZT will prevent progression of clinical disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HIVIG may be an effective agent that either alone or in combination with AZT will prevent&#xD;
      progression of clinical disease.&#xD;
&#xD;
      Participants are randomized to receive either oral AZT or HIVIG. Patients may receive&#xD;
      treatment for a maximum of 48 weeks. Patients are evaluated during treatment at weeks 2, 4,&#xD;
      and every 4 weeks thereafter. Infants who are receiving HIVIG initially are treated with the&#xD;
      appropriate age-adjusted dose of oral AZT in addition to HIVIG if they meet clinical disease&#xD;
      progression criteria. All participants who have completed 48 weeks of treatment or who are&#xD;
      discontinued from treatment are followed every 3 months for an additional 48 weeks. This&#xD;
      follow-up may be conducted over the telephone.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <primary_completion_date type="Actual">May 1991</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>112</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-HIV Immune Serum Globulin (Human)</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Recommended:&#xD;
&#xD;
          -  Standard immunizations. Should repeat MMR 3 months after discontinuing study.&#xD;
&#xD;
          -  Benadryl and/or aspirin.&#xD;
&#xD;
          -  Pneumocystis carinii pneumonia prophylaxis.&#xD;
&#xD;
          -  Systemic ketoconazole and acyclovir, or oral nystatin for acute therapy.&#xD;
&#xD;
          -  Aerosol ribavirin for short-term treatment of RSV.&#xD;
&#xD;
        Concurrent Treatment:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Blood transfusion.&#xD;
&#xD;
        Patients must have the following:&#xD;
&#xD;
          -  Parent or guardian available to give written informed consent.&#xD;
&#xD;
          -  Protocol requires prior Institutional Review Board (IRB) approval before any subject&#xD;
             is entered into study.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Gammaglobulin, intravenous (IV) or intramuscular (IM).&#xD;
&#xD;
          -  Immunoglobulin, IV (IVIG).&#xD;
&#xD;
          -  Maternal antiretroviral treatment during pregnancy.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following conditions or symptoms are excluded:&#xD;
&#xD;
          -  Symptomatic of any class P-2 symptoms (except lymphadenopathy at time of study entry.&#xD;
&#xD;
          -  Presence of serious acute infection requiring parenteral treatment at time of study&#xD;
             entry.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Prophylaxis for oral candidiasis or otitis media or other infections.&#xD;
&#xD;
          -  Immunoglobulin therapy (except single dose or for hypogammaglobulinemia).&#xD;
&#xD;
          -  Ketoconazole, acyclovir, or nystatin for prophylaxis.&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  Symptomatic of any class P-2 symptoms (except lymphadenopathy at time of study entry.&#xD;
&#xD;
          -  Presence of serious acute infection requiring parenteral treatment at time of study&#xD;
             entry.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Antiretroviral treatment or experimental treatment within 2 weeks of entry.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Day</minimum_age>
    <maximum_age>3 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Connor E</last_name>
    <role>Study Chair</role>
  </overall_official>
  <reference>
    <citation>Spector SA, Gelber RD, McGrath N, Wara D, Barzilai A, Abrams E, Bryson YJ, Dankner WM, Livingston RA, Connor EM. A controlled trial of intravenous immune globulin for the prevention of serious bacterial infections in children receiving zidovudine for advanced human immunodeficiency virus infection. Pediatric AIDS Clinical Trials Group. N Engl J Med. 1994 Nov 3;331(18):1181-7. doi: 10.1056/NEJM199411033311802.</citation>
    <PMID>7935655</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <keyword>Drug Therapy, Combination</keyword>
  <keyword>Zidovudine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Immune Sera</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

